South Korea · Delayed Price · Currency is KRW D&D Pharmatech Statistics
Total Valuation
D&D Pharmatech has a market cap or net worth of KRW 3.92 trillion. The enterprise value is 3.91 trillion.
| Market Cap | 3.92T |
| Enterprise Value | 3.91T |
Important Dates
The next estimated earnings date is Friday, August 14, 2026.
| Earnings Date | Aug 14, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
D&D Pharmatech has 43.80 million shares outstanding. The number of shares has increased by 3.53% in one year.
| Current Share Class | 43.80M |
| Shares Outstanding | 43.80M |
| Shares Change (YoY) | +3.53% |
| Shares Change (QoQ) | -69.65% |
| Owned by Insiders (%) | 16.82% |
| Owned by Institutions (%) | 19.00% |
| Float | 34.35M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 1,302.67 |
| PB Ratio | 53.07 |
| P/TBV Ratio | 90.33 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -168.35 |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | -156.63 |
Financial Position
The company has a current ratio of 8.02, with a Debt / Equity ratio of 0.08.
| Current Ratio | 8.02 |
| Quick Ratio | 4.98 |
| Debt / Equity | 0.08 |
| Debt / EBITDA | n/a |
| Debt / FCF | -0.24 |
| Interest Coverage | -89.33 |
Financial Efficiency
Return on equity (ROE) is -35.02% and return on invested capital (ROIC) is -66.48%.
| Return on Equity (ROE) | -35.02% |
| Return on Assets (ROA) | -24.72% |
| Return on Invested Capital (ROIC) | -66.48% |
| Return on Capital Employed (ROCE) | -41.26% |
| Weighted Average Cost of Capital (WACC) | 10.92% |
| Revenue Per Employee | n/a |
| Profits Per Employee | n/a |
| Employee Count | n/a |
| Asset Turnover | 0.03 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | -1.35B |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +328.46% in the last 52 weeks. The beta is 1.21, so D&D Pharmatech's price volatility has been higher than the market average.
| Beta (5Y) | 1.21 |
| 52-Week Price Change | +328.46% |
| 50-Day Moving Average | 76,324.00 |
| 200-Day Moving Average | 72,900.25 |
| Relative Strength Index (RSI) | 53.08 |
| Average Volume (20 Days) | 1,566,689 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, D&D Pharmatech had revenue of KRW 3.01 billion and -23.20 billion in losses. Loss per share was -774.46.
| Revenue | 3.01B |
| Gross Profit | 2.99B |
| Operating Income | -35.80B |
| Pretax Income | -25.36B |
| Net Income | -23.20B |
| EBITDA | -30.29B |
| EBIT | -35.80B |
| Loss Per Share | -774.46 |
Balance Sheet
The company has 24.57 billion in cash and 5.99 billion in debt, with a net cash position of 18.58 billion or 424.16 per share.
| Cash & Cash Equivalents | 24.57B |
| Total Debt | 5.99B |
| Net Cash | 18.58B |
| Net Cash Per Share | 424.16 |
| Equity (Book Value) | 73.95B |
| Book Value Per Share | 1,711.15 |
| Working Capital | 40.17B |
Cash Flow
In the last 12 months, operating cash flow was -24.90 billion and capital expenditures -36.59 million, giving a free cash flow of -24.94 billion.
| Operating Cash Flow | -24.90B |
| Capital Expenditures | -36.59M |
| Depreciation & Amortization | 5.51B |
| Net Borrowing | -1.88B |
| Free Cash Flow | -24.94B |
| FCF Per Share | -569.25 |
Margins
| Gross Margin | 99.18% |
| Operating Margin | -1,188.29% |
| Pretax Margin | -841.82% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
D&D Pharmatech does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -3.53% |
| Shareholder Yield | -3.53% |
| Earnings Yield | -0.59% |
| FCF Yield | -0.64% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
The last stock split was on November 13, 2025. It was a forward split with a ratio of 4.
| Last Split Date | Nov 13, 2025 |
| Split Type | Forward |
| Split Ratio | 4 |
Scores
D&D Pharmatech has an Altman Z-Score of 70.43 and a Piotroski F-Score of 1.
| Altman Z-Score | 70.43 |
| Piotroski F-Score | 1 |